Yin-jun Lou

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
BACKGROUND Recently, the all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO) protocol has become a promising first-line therapeutic approach in patients with newly diagnosed acute promyelocytic leukemia (APL), but its benefits compared with standard ATRA plus chemotherapy regimen needs to be proven. Herein, we conducted a meta-analysis comparing the(More)
npg CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia Yin-jun LOU D isruption of normal differentiation is an important link in tumorigen-esis, but understanding the molecular mechanisms underlying this process is still limited. Acute myeloid leukemia (AML) is characterized by an accumulation of immature myeloid precursor(More)
A cute myeloid leukemia (AML) is a highly malignant hematopoietic tumor. The use of all-trans retinoic acid (ATRA) and arsenic trioxide, which began from China, has resulted in revolution of the acute promyelocytic leukemia (APL) that appears curable in more than 70% of patients [1]. However , the treatment regimen for non-APL AML particularly in older(More)
  • 1